he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源位址
- 2022-05-03Sensible Medical:基于“透视墙”技术研发“穿戴”电子设备,测量肺积液管理心衰患者
- 2022-04-252013年国际抗癫痫联合会抗癫痫药剂使用指南
- 2022-04-21癫痫孕妇用于抗癫痫药物会增加流产风险吗?
- 2022-02-07未婚为什么会患癫痫病 癫痫病症状
- 2022-01-24常见的癫痫病发作的副作用有哪些
- 2022-01-10妇女为什么会患癫痫病 癫痫病症状
- 胎盘滞留:三种宫缩应该选择哪一种?
- 白发怎么变黑发 治疗白发变黑的方法
- 每个女人都是江湖……
- 非淋性尿道炎症状 非淋性尿道炎怎么办?
- 癫痫治愈费用
- 预测癫痫患者再入院风险
- 为什么方海市的血能救她?原因有二
- 【预约直播】铿锵的论道 不炎,越来越多--「郁金香论坛」学术沙龙即将举行
- 2015 神经系统疾病诊疗进展
- 癫痫定位新方法:无框架立体定向脑电图技术
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 罕见病例:自发性颞极性扩张伴癫痫发作
- NICE推荐将Elmiron(戊糖多钠)治疗膀胱疼痛综合征
- 第二届微创、超声介入学科发展及临床应用研讨会
- 小心!这些行为易引起子宫内膜炎
- Pharmaceutics:局部治疗念珠菌感染的脂质体槲皮素和无食子酸
- 月经提前的原因是什么?
- 继发性癫痫能治愈吗 治疗癫痫有几个步骤
- 多囊卵巢综合征严重吗?不积极治疗会导致不孕!
- 著名女演员愤怒地告诉莆田妇科医院 要求在全国媒体上公开道歉
- 互联网医疗和医生如何依靠服务而不开药?
- 怀孕期间总是感到疼痛。发生了什么事?看完这篇文章,我相信你会明白的。
- 溢液都有哪些原因?有些是按出来的!排毒吗?警惕血性溢液!
- BMC Complement Med Ther:丁香可用于治疗念珠菌性炎症
- 结核病的早期症状是什么?
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 上海率先探索异地就医门诊费直接结算
- GW制制剂Epidiolex治疗Dret综合征获欧盟孤儿制剂资格
- 治疗腹型癫痫病并不需要多少钱
- 幼儿癫痫病的腹泻
- Circ Ep:异性恋绝经后雌激素治疗或增加房颤风险
- 青年人得了癫痫病有什么症状
- 癫痫的症状 睡觉中犯癫痫会有哪些发挥
- 20130301河南卫视养生节目:安晓光谈癫痫病病因
- 北京:1月20日起无偿献血者临床用血费用必要减免
- 怎么样对原发性癫痫病进行时治疗
- 疗程癫痫病偏方哪些好啊
- 不伴丘脑内侧硬化的丘脑癫痫患者隔核增大
- 癫痫病需要怎样来展开诊断
- 清心养生堂:杨全兴讲如何预防儿童癫痫